Studio Investment Management LLC Acquires 172 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Studio Investment Management LLC boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 3.8% in the third quarter, Holdings Channel reports. The firm owned 4,674 shares of the company’s stock after purchasing an additional 172 shares during the quarter. Studio Investment Management LLC’s holdings in Henry Schein were worth $341,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Henry Schein by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company’s stock valued at $85,662,000 after buying an additional 6,184 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Henry Schein by 37.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,003,041 shares of the company’s stock worth $73,122,000 after buying an additional 274,756 shares during the period. Cypress Capital Group acquired a new position in Henry Schein in the 3rd quarter valued at about $224,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Henry Schein by 5.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 122,721 shares of the company’s stock worth $8,946,000 after acquiring an additional 6,826 shares during the last quarter. Finally, Nuance Investments LLC boosted its stake in Henry Schein by 22.3% in the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after purchasing an additional 414,748 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the transaction, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. The trade was a 12.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Trading Up 1.8 %

NASDAQ HSIC opened at $75.08 on Friday. The company has a market cap of $9.36 billion, a price-to-earnings ratio of 30.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business’s fifty day moving average is $70.80 and its 200 day moving average is $69.72.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same period last year, the firm posted $1.32 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. UBS Group cut their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Barrington Research restated an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.